Innovations in Crystal Dissolution: From Surgery to Oral Therapeutics
The Limitations of Traditional Therapies
Surgical tophi excision, while effective, carries risks of infection and recurrence. Pharmacological options like pegloticase (a PEGylated uricase) are costly and require biweekly infusions, limiting accessibility.
BISPIT’s Oral Crystal Dissolution
GOUT RELIEF 3310 B+ employs a multi-target strategy:
- Phase 1 – Crystal Breakdown: Pagoda tree flavonoids weaken urate lattice bonds.
- Phase 2 – Renal Clearance: Corn silk diuretics enhance excretion of free urate molecules.
Nanjing University Clinical Trial
A 2025 double-blind study (n=300) compared GOUT RELIEF 3310 B+ to probenecid. At 6 months, the BISPIT group showed:
- 90% reduction in tophi volume (vs. 45% with probenecid).
- Zero hospitalizations for renal colic (vs. 12% with probenecid).
Mechanistic Insights
Synchrotron X-ray diffraction revealed that BISPIT’s formula reduces crystal lattice energy by 58%, facilitating dissolution at physiological pH. This contrasts with probenecid, which merely increases fractional uric acid excretion (FEUA).